<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> syndrome (IRS) is associated with <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> and increased <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> risk </plain></SENT>
<SENT sid="1" pm="."><plain>A novel method for detailed analyses of <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> subclass sizes and particle concentrations that uses nuclear magnetic resonance (NMR) of whole sera has become available </plain></SENT>
<SENT sid="2" pm="."><plain>To define the effects of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, we measured <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> using both NMR <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> subclass analysis and conventional <z:chebi fb="23" ids="18059">lipid</z:chebi> panel, and insulin sensitivity as the maximal <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal rate (GDR) during hyperinsulinemic clamps in 56 insulin sensitive (IS; mean +/- SD: GDR 15.8 +/- 2.0 mg </plain></SENT>
<SENT sid="3" pm="."><plain>kg(-1) </plain></SENT>
<SENT sid="4" pm="."><plain>min(-1), fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> [FBG] 4.7 +/- 0.3 mmol/l, BMI 26 +/- 5), 46 insulin resistant (IR; GDR 10.2 +/- 1.9, FBG 4.9 +/- 0.5, BMI 29 +/- 5), and 46 untreated subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (GDR 7.4 +/- 2.8, FBG 10.8 +/- 3.7, BMI 30 +/- 5) </plain></SENT>
<SENT sid="5" pm="."><plain>In the group as a whole, regression analyses with GDR showed that progressive <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> was associated with an increase in <z:chebi fb="1" ids="39027">VLDL</z:chebi> size (r = -0.40) and an increase in large <z:chebi fb="1" ids="39027">VLDL</z:chebi> particle concentrations (r = -0.42), a decrease in <z:chebi fb="15" ids="39026">LDL</z:chebi> size (r = 0.42) as a result of a marked increase in small <z:chebi fb="15" ids="39026">LDL</z:chebi> particles (r = -0.34) and reduced large <z:chebi fb="15" ids="39026">LDL</z:chebi> (r = 0.34), an overall increase in the number of <z:chebi fb="15" ids="39026">LDL</z:chebi> particles (r = -0.44), and a decrease in <z:chebi fb="17" ids="39025">HDL</z:chebi> size (r = 0.41) as a result of <z:mpath ids='MPATH_63'>depletion</z:mpath> of large <z:chebi fb="17" ids="39025">HDL</z:chebi> particles (r = 0.38) and a modest increase in small <z:chebi fb="17" ids="39025">HDL</z:chebi> (r = -0.21; <z:hpo ids='HP_0000001'>all</z:hpo> P &lt; 0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>These correlations were also evident when only normoglycemic individuals were included in the analyses (i.e., IS + IR but no <z:mp ids='MP_0002055'>diabetes</z:mp>), and persisted in multiple regression analyses adjusting for age, BMI, sex, and race </plain></SENT>
<SENT sid="7" pm="."><plain>Discontinuous analyses were also performed </plain></SENT>
<SENT sid="8" pm="."><plain>When compared with IS, the IR and <z:mp ids='MP_0002055'>diabetes</z:mp> subgroups exhibited a two- to threefold increase in large <z:chebi fb="1" ids="39027">VLDL</z:chebi> particle concentrations (no change in medium or small <z:chebi fb="1" ids="39027">VLDL</z:chebi>), which produced an increase in serum <z:chebi fb="4" ids="17855">triglycerides</z:chebi>; a decrease in <z:chebi fb="15" ids="39026">LDL</z:chebi> size as a result of an increase in small and a reduction in large <z:chebi fb="15" ids="39026">LDL</z:chebi> subclasses, plus an increase in overall <z:chebi fb="15" ids="39026">LDL</z:chebi> particle concentration, which together led to no difference (IS versus IR) or a minimal difference (IS versus <z:mp ids='MP_0002055'>diabetes</z:mp>) in <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi>; and a decrease in large cardioprotective <z:chebi fb="17" ids="39025">HDL</z:chebi> combined with an increase in the small <z:chebi fb="17" ids="39025">HDL</z:chebi> subclass such that there was no net significant difference in <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that 1) <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> had profound effects on <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> size and subclass particle concentrations for <z:chebi fb="1" ids="39027">VLDL</z:chebi>, <z:chebi fb="15" ids="39026">LDL</z:chebi>, and <z:chebi fb="17" ids="39025">HDL</z:chebi> when measured by NMR; 2) in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, the <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> subclass alterations are moderately exacerbated but can be attributed primarily to the underlying <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>; and 3) these <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>-induced changes in the NMR <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> subclass profile predictably increase risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> but were not fully apparent in the conventional <z:chebi fb="23" ids="18059">lipid</z:chebi> panel </plain></SENT>
<SENT sid="10" pm="."><plain>It will be important to study whether NMR <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> subclass parameters can be used to manage risk more effectively and prevent <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> in patients with the IRS </plain></SENT>
</text></document>